UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: Randomised trial long term outcomes

Manousou, P; Cholongitas, E; Samonakis, D; Tsochatzis, E; Corbani, A; Rodríguez-Perálvarez, M; Patch, D; ... McCormick, PA; + view all (2014) Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: Randomised trial long term outcomes. Gut , 63 (6) 1005 - 1013. 10.1136/gutjnl-2013-305606. Green open access

[thumbnail of Gut-2014-Manousou-1005-13.pdf]
Preview
PDF
Gut-2014-Manousou-1005-13.pdf

Download (1MB)

Abstract

Objective: Early results of a randomised trial showed reduced fibrosis due to recurrent HCV hepatitis with tacrolimus triple therapy (TT) versus monotherapy (MT) following transplantation for HCV cirrhosis. We evaluated the clinical outcomes after a median 8 years of follow-up, including differences in fibrosis assessed by collagen proportionate area (CPA). Design: 103 consecutive liver transplant recipients with HCV cirrhosis receiving cadaveric grafts were randomised to tacrolimus MT (n=54) or TT (n=49) with daily tacrolimus (0.1 mg/kg divided dose), azathioprine (1 mg/kg) and prednisolone (20 mg), the last tailing off to zero by 6 months. Both groups had serial transjugular biopsies with hepatic venous pressure gradient (HVPG) measurement. Time to reach Ishak stage 4 was the predetermined endpoint. CPA was measured in all biopsies. Factors associated with HCV recurrence were evaluated. Clinical decompensation was the first occurrence of ascites/hydrothorax, variceal bleeding or encephalopathy. Results: No significant preoperative, peri-operative or postoperative differences between groups were found. During 96 months median follow-up, stage 4 fibrosis was reached in 19 MT/11 TT with slower fibrosis progression in TT (p=0.009). CPA at last biopsy was 12% in MT and 8% in TT patients (p=0.004). 14 MT/three TT patients reached HVPG≥10 mm Hg (p=0.002); 10 MT/ three TT patients, decompensated. Multivariately, allocated MT (p=0.047, OR 3.23, 95% CI 1.01 to 10.3) was independently associated with decompensation: 14 MT/ seven TT died, and five MT/ four TT were retransplanted. Conclusions: Long term immunosuppression with tacrolimus, azathioprine and short term prednisolone in HCV cirrhosis recipients resulted in slower progression to severe fibrosis assessed by Ishak stage and CPA, less portal hypertension and decompensation, compared with tacrolimus alone. ISRCTN94834276 - Randomised study for immunosuppression regimen in liver transplantation.

Type: Article
Title: Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: Randomised trial long term outcomes
Open access status: An open access version is available from UCL Discovery
DOI: 10.1136/gutjnl-2013-305606
Publisher version: http://dx.doi.org/10.1136/gutjnl-2013-305606
Additional information: © 2014 BMJ Publishing Group Ltd & British Society of Gastroenterology. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/3.0/
URI: https://discovery-pp.ucl.ac.uk/id/eprint/1431256
Downloads since deposit
7,626Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item